20 recruiting, 8 active not recruiting, 7 completed, 7 not yet recruiting. 26 Phase 2, 9 Not applicable, 5 Phase 1, 4 Phase 3, 3 Early Phase 1.
Follow Oropharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Oropharyngeal Squamous Cell Carcinoma trials Research Report on Oropharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2026-12-01 | 2026-10-08 | |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-27 | 2026-10-22 |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer Lymphatic mapping with SPECT-CT, Bilateral neck radiotherapy, Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy - Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers | Not applicable | Not yet recruiting | UNICANCER | 128 | 2026-09-01 | 2026-07-21 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 132 | 2026-09-01 | 2026-08-14 |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel - HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 70 | 2026-07-22 | 2026-06-04 |
| Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers Acupuncture - Xerostomia, Head Cancer | Not applicable | Not yet recruiting | National University Hospital, Singapore | 50 | 2026-06-01 | 2026-06-29 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma Cisplatin, Radiotherapy - Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sara Medek | 31 | 2026-05-13 | 2026-05-18 |
| Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma Induction Chemo-Immunotherapy, Lattice Radiotherapy - Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | NYU Langone Health | 60 | 2026-05-01 | 2026-02-23 |
| Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer Compartmentalized Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Olgun Elicin | 50 | 2026-01-15 | 2026-08-27 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer Pre-Radiation Dental Evaluation/Sample Collection, Pre-Study Visit, Oral Medicine Consultation Visit/Sample Collection - Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus Infection | Withdrawn | Wake Forest University Health Sciences | 2025-08-01 | 2025-07-31 | ||
| Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma. Radiation Therapy - Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Utah | 42 | 2025-07-23 | 2026-10-09 |
| Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Recruiting | University Hospital, Strasbourg, France | 30 | 2025-07-11 | 2026-01-15 | |
| Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma Sintilimab+Cetuximab - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 50 | 2025-07-01 | 2025-07-23 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers Fludarabine, Cyclophosphamide, NEXI-003 T cells - Oropharyngeal Cancer, Human Papilloma Virus | Phase 1 | Not yet recruiting | NexImmune Inc. | 36 | 2025-03-31 | 2024-01-16 |
| People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity Group Meeting (Focus Group), Questionnaires - HIV Infections, Oral Squamous Cell Carcinoma | Active not recruiting | University of California, San Francisco | 133 | 2025-02-13 | 2026-09-11 | |
| Validity of Viome's Oral/throat Cancer Test Oral/Throat cancer test - Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma | Recruiting | Viome | 1000 | 2025-01-27 | 2025-01-29 | |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
Showing 20 of 55. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (55) · Head and Neck Neoplasms (14) · Oropharyngeal Neoplasms (13) · Carcinoma (9) · Laryngeal Neoplasms (7) · Hypopharyngeal Neoplasms (6) · Mouth Neoplasms (6) · Nasopharyngeal Carcinoma (6) · Carcinoma, Squamous Cell (4) · Papillomavirus Infections (4) · Salivary Gland Neoplasms (2) · Carcinoma, Adenoid Cystic (1) · Coitus (1) · HIV Infections (1) · Neoplasm Metastasis (1)
Neoplasms (55) · Neoplasms by Histologic Type (55) · Neoplasms by Site (55) · Neoplasms, Glandular and Epithelial (55) · Carcinoma, Squamous Cell (51) · Carcinoma (46) · Head and Neck Neoplasms (41) · Stomatognathic Diseases (19) · Otorhinolaryngologic Diseases (18) · Otorhinolaryngologic Neoplasms (18) · Pharyngeal Diseases (18) · Pharyngeal Neoplasms (18) · Mouth Diseases (9) · Laryngeal Diseases (7) · Respiratory Tract Diseases (7)
Cisplatin (11) · Magnetic Resonance Spectroscopy (7) · Radiotherapy, Intensity-Modulated (6) · Specimen Handling (6) · Carboplatin (5) · Radiotherapy (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Platinum (4) · durvalumab (4) · Immunoglobulin G (3) · Paclitaxel (3) · Radiation (3) · Radiotherapy, Image-Guided (3) · 130-nm albumin-bound paclitaxel (2) · Biopsy (2)
National Cancer Institute (NCI) (4) · Dana-Farber Cancer Institute (2) · Emory University (2) · Ohio State University Comprehensive Cancer Center (2) · Radboud University Medical Center (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · University of Maryland, Baltimore (2) · Wake Forest University Health Sciences (2) · Canadian Cancer Trials Group (1) · Centro di Riferimento Oncologico - Aviano (1) · Copenhagen University Hospital, Rigshospitalet (1) · ECOG-ACRIN Cancer Research Group (1) · Hookipa Biotech GmbH (1) · Icahn School of Medicine at Mount Sinai (1) · ImmunityBio, Inc. (1)
United States (26) · Canada (4) · China (4) · France (4) · Italy (3) · Netherlands (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Denmark (1) · Ireland (1) · Singapore (1) · Slovenia (1) · Spain (1) · Switzerland (1)
Alexandra Hernandez Levenston, PhD, MPH (1) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · Anna Spreafico (1) · Ari Rosenberg (1) · Ashley Tay (1) · Ben Panizza, Assoc Prof (1) · Catriona Douglas (1) · Charalampos Floudas, M.D. (1) · Cristina Julian (1) · Danielle MacNeil, M.D. (1) · David M Brizel (1) · David Pass, Mr (1) · Eleni M Rettig, MD (1) · Elisabetta Fratta, PhD (1) · Eric Miller, MD, PhD (1)
PMID 33605440, PMID 34980038, PMID 36125263, PMID 39317508, PMID 39551064, PMID 39679923, PMID 39715483, PMID 40855191
P30CA138292 (2), U10CA180868 (2), K24DC022077 (1), P30CA012197 (1), P30CA016058 (1), R03DE032972 (1), U01DE029754 (1), U10CA180820 (1), UG1CA189867 (1), UM1CA186691 (1)